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Background: The appearance of smear-positivity but culture-negativity (SPCN) for acid-fast bacilli among sputum
specimen is frequently found in pulmonary tuberculosis (TB) patients during treatment. This study aimed to investigate
clinical risk factors, impacts on treatment course, and relapse pattern associated with sputum SPCN.
Methods: We retrospectively enrolled 800 patients with culture-proven pulmonary TB who were receiving standard
treatment and follow-up at six TB-referral hospitals in Taiwan between January 2006 and December 2007. Relevant
patient characteristics and chemotherapy data were analyzed for associations with incidence of SPCN. Data from
patients who relapsed within 3 years after completing treatment were analyzed for associations with SPCN during
treatment.
Results: Of the 800 subjects, 111 (13.8%) had sputum SPCN during treatment. Three factors were found to predict the
development of SPCN; namely, high initial acid-fast staining grading (OR, 3.407; 95% CI, 2.090–5.553), cavitation on
chest-X ray films (OR, 2.217; 95% CI, 1.359–3.615), and smoking (OR, 1.609; 95% CI, 1.006–2.841). Patients with SPCN
had longer treatment duration (rifampicin: 284 ± 91 vs. 235 ± 69 days, P <0.001; isoniazid: 289 ± 90 vs. 234 ± 69 days,
P < 0.001) than those without SPCN. Finally, the rate of relapse within 3 years of completing treatment was similar for
groups with/without SPCN (2.7%, 3/111 vs. 1.0%, 7/689, respectively; P = 0.15).
Conclusions: In conclusion, severity of infection was a major risk factor for SPCN during treatment; however, the
relapse rate within 3 years of completing treatment was not affected by the appearance of SPCN.
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Tuberculosis (TB) remains a leading health problem
worldwide. The causal pathogen Mycobacterium tubercu-
losis (Mtb) has extraordinarily adaptive strategies for differ-
ent stressful circumstances, including anti-mycobacterial
treatment [1,2]. Because smear-positivity for acid-fast
bacilli in sputum specimens indicates a high mycobacterial
load, culture-positivity for mycobacteria is expected in
most cases. However, during antimycobacterial treatment,
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unless otherwise stated.culture-positivity for mycobacteria. Two recent studies
have reported culture-negativity with smear-positivity at
the end of the second month of intensive treatment in
44.2% of patients (50/113) in Taiwan and 46.45% (40/86)
in Cameroon [3,4]. Additionally, in our previous study
investigating 111 patients with smear-positivity in the fifth
month of treatment, we found that 71.6% of cases (83/111)
had smear-positive but culture-negative (SPCN) sputum
[5]. Given that treatment failure is currently defined as
positive sputum smear or culture in the fifth month or
later of treatment, it is potentially risky to assess treatment
failure by sputum smear alone because of the possibility of
SPCN [6]. Such SPCN phenomena have great clinical
impact in the long period of waiting for culture results of
smear-positive sputum samples. Uncertainty about culturehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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treatment failure [7,8]. Therefore, longitudinal studies are
required to investigate the outcomes of SPCN phenomenon
during treatment. In this study, we aimed to investigate risk
factors, including severity of TB and clinical predisposing
factors for TB, and their impacts on treatment and relapse
of patients with sputum SPCN.
Methods
This study was conducted retrospectively in six TB-referral
hospitals in Taiwan. The Directly Observed Therapy
(DOT) program was launched in Taiwan in April 2006
and DOT coverage of smear positive cases reached
92.6% in 2007 [9].
All patients reported as new pulmonary TB cases from
January 2006 to December 2007 were identified by review-
ing the databases of the Central Disease Control (CDC),
Taiwan. From January 2006 to December 2007, 3852
patients were identified as new cases in the six TB referral
hospitals. Patients were excluded if the TB diagnosis had
been revised (439), there was no mycobacterial evidence
of TB (981), or they had an inadequate duration of follow-
up resulting from being transferred out (306) or dying
within the initial 2 months (399). Patients who had re-
ceived initial phase treatment at other hospitals (525), had
rifampicin-resistant TB (222), were unable to tolerate first
line treatment (53), or whose medication had been inter-
rupted for longer than 2 months (127) were also excluded.
Thus, 800 patients with culture-proven TB who hadFigure 1 Flow chart showing enrolment process.received the standard regimen and undergone adequate
follow-up were enrolled in this study. The process of
enrollment is summarized in Figure 1.
Cases of relapse were also identified by reviewing the
databases of the CDC; and diagnoses of relapse were
based on both chest-X ray films (CXR) and adequate
sputum mycobacterial evidence. Sputum SPCN was de-
fined as sputum that was smear-positive for acid-fast ba-
cilli but did not yield any mycobacteria on either liquid
or solid media. Our research was performed in compli-
ance with the Helsinki Declaration and approval was
obtained from our local ethics committee (Institutional
Review Board of the Chung Shan Medical University
Hospital, Reference No: CS11051).
In 2004, Taiwan CDC established the National Reference
Laboratory of Mycobacteriology, which is responsible for
formulating standard operating procedures and assessing
and regulating the quality control programs of all labora-
tories in the mycobacterial laboratory examination net-
work [10]. Briefly, the relevant standard procedures were
performed as follows. Early-morning sputum samples were
decontaminated with NaOH. Ziehl–Nielsen stained smears
were examined and graded according to the American
Thoracic Society guidelines [11]. As for mycobacterial
culture, solid culture media, such as Lowenstein–Jensen
media and 7H10 or 7H11 media, and liquid culture media,
such as BacT/ALERT 3D (bioMerieux, Lyon, France) and
the BACTEC MGIT (BACTEC Mycobacterium Growth
Indicator Tube, MGIT 960 system, Becton-Dickinson,
Table 1 Characteristics of patients with and without






N = 800 N = 111 N = 689
Basic data
Age (years) 55 ± 20 54 ± 18 55 ± 21 p = 0.784
Sex (male) 564 (71) 88 (79) 476 (69) p = 0.033
Body Weight
(kgs)
57 ± 11 56 ± 11 57 ± 11 p = 0.332
Smoking 311 (39) 63 (57) 248 (36) p < 0.001
Alcohol
consumption
171 (21) 35 (32) 136 (20) p = 0.008
Diabetes
mellitus
182 (23) 38 (34) 144 (21) p = 0.003
HbA1C (%) 9.8 ± 3.2 10.6 ± 2.8 9.6 ± 3.3 p = 0.149
Chest-X ray findings
Cavity formation 285 (36) 72 (65) 213 (31) p < 0.001
Cavity > = 4 cm 146 (18) 47 (42) 99 (14) p < 0.001




Negative 376 (47) 5 (5) 371 (54)
1+ 162 (20) 32 (29) 130 (19)
2+ 106 (13) 25 (23) 81 (12)
3+ 73 (9) 18 (16) 55 (8)
4+ 83 (10) 31 (28) 52 (8)
Symptoms
Cough 557 (70) 83 (75) 474 (69) p = 0.354
Haemoptysis 74 (9) 12 (14) 62 (9) p = 0.727
Fever 141 (18) 21 (19) 120 (17) p = 0.893
Body weight
loss (>5%)
194 (24) 32 (29) 162 (24) p = 0.468
Laboratory findings
WBC (cells/μl) 8469 ± 6840 8758± 2772 8423± 7287 p = 0.136
Hemoglobin
(g/dL)
13 ± 2 13 ± 2 13 ± 2 p = 0.995
Albumin
(mg/dL)
3.7 ± 2.2 3.4 ± 0.6 3.8 ± 2.5 p = 0.390
Creatinine
(mg/dL)
1.1 ± 0.8 1.09 ± 0.5 1.15 ± 0.8 p = 0.450
Data are presented as N (%) or mean ± standard deviation.
Abbreviations: SPCN smear-positive but culture-negative, HbA1C Hemoglobin
A1c.
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addition to morphology and growth rate of the bacterial
colonies, biochemical tests, and molecular assays were
used to identify Mtb [12]. In accordance with the tubercu-
losis treatment guidelines in Taiwan [13], all patients’ spu-
tum smears and cultures had been checked in the second
and fifth months after initiation of treatment; monthly
sputum checks had also been performed until sputum
conversion in all patients with positive smears.
The medical records of enrolled patients were reviewed
to obtain data on associated medical conditions, labora-
tory findings, hemoglobin A1C at the start of anti-TB
treatment, serial sputum results, treatment regimen, and
outcomes. CXRs at the start of treatment were evaluated
by two pulmonologists from the Chest Hospital who were
blinded to the clinical data. When their interpretations dif-
fered, the image was further reviewed by a third chest spe-
cialist who was also blinded to the results.
Statistics
Data are presented as the frequencies (n) or percentages
(%) for categorical factors and as means ± standard devi-
ations for continuous factors. Categorical variables were
compared using the χ2 test and differences in continuous
variables were analyzed using the Mann–Whitney U test.
Multivariate logistic regression analysis was used to de-
termine independent variables that predicted SPCN. The
Cochran–Armitage trend test was used to assess differ-
ences in trends in acid-fast smear (AFS) grading and
cavity size in patients with or without sputum SPCN.
Statistical significance was set at P < 0.05, two-sided. All
data were analyzed using SPSS version 16.0 (SPSS, Chicago,
IL, USA).
Ethical approval
This study was approved by the Institutional Review
Board of the Chung Shan Medical University Hospital
(CSMUH No: CS11051).
Results
Of the 800 enrolled cases, 111 (13.9%) developed SPCN
in sputum during their treatment. Age, body weight,
clinical symptoms, and laboratory findings were similar
between patients with/without SPCN (Table 1). Patients
with sputum SPCN were more likely to be male (79% vs.
69%, P = 0.033), to be smokers (57% vs. 36%, P < 0.001),
to consume alcohol (32% vs. 20%, P = 0.008), and to have
type 2 diabetes mellitus (34% vs. 21%, P = 0.003) than
patients without sputum SPCN. Patients with sputum
SPCN clearly had more severe TB than those without
sputum SPCN, as evidenced by the former being more
likely to have cavitated lesions (65% vs. 31%, P < 0.001)
and large cavities (>4 cm) (42% vs. 14%, P < 0.001) on
CXRs as well as higher sputum AFS grading thanpatients without sputum SPCN. On univariate analysis,
the statistical power for cavitated lesions (P < 0.001),
AFS grading (P < 0.001), and smoking (P < 0.001) were
stronger than for maleness (P = 0.033), alcohol consump-
tion (P = 0.008), and type 2 diabetes mellitus (P = 0.003),
which may explain why subsequent multivariate analysis
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smoking predicted development of SPCN.
To clarify the time course of SPCN and the effect of
TB severity on the development of SPCN, we correlated
sputum smear and culture conversion curve with TB se-
verity. In patients with low initial AFS grading or no cav-
ities on CXRs, the sputum smear conversion and culture
conversion curves were close to each other and sputum
smear conversion mostly preceded sputum culture con-
version (Figure 2). However, in patients with high initial
AFS grading or cavities on CXR, there was discordance
between sputum smear and culture conversion and
culture conversion preceded sputum smear conversion.
Multivariate logistical regression identified three variables
that were independently associated with the presence of
sputum SPCN during treatment (Table 2). These were high
initial acid-fast stain grading (>1+) (OR, 3.407; 95% CI,
2.090–5.553), cavities on CXR (OR, 2.217; 95% CI, 1.359–
3.615), and smoking (OR, 1.609; 95% CI, 1.006–2.841). To
further explore the effect of TB severity on the develop-
ment of sputum SPCN, we subdivided patients with cav-
ities on CXR into those with cavities larger or less than
4 cm in diameter and their AFS grading was classified asFigure 2 Cumulative percentages of positive sputum mycobacterial s
(dotted line) in patients with low (≤1+) and high acid-fast stain gradin
without cavity formation on chest-X ray films (B). SPCN, smear-positivenegative, 1+ and ≥2+. We found that proportions of spu-
tum SPCN increased with TB severity as assessed by both
cavitation and AFS grading in a dose-dependent manner
(Figure 3). Thus, taken together, the data demonstrated that
severe infection, characterized by high initial sputum AFS
grading and cavities on CXR, was the key risk factor for
the occurrence of sputum SPCN during anti-tuberculous
treatment.
To further investigate the clinical impact of sputum
SPCN, we assessed treatment regimens, outcomes, and
relapse rate during the 3-year follow-up after completing
treatment (Table 3) and found that the 111 patients with
sputum SPCN received treatment for longer than the 689
without sputum SPCN. The durations of treatment with
rifampicin and isoniazid, the two most important medica-
tions in the continuation phase, were both longer in pa-
tients with than without sputum SPCN (rifampicin: 284 ±
91 vs. 235 ± 69 days, respectively, P < 0.001; isoniazid:
289 ± 90 vs. 234 ± 69 days, respectively, P < 0.001). Other
first line medications used in the initial phase, including
ethambutol, pyrazinamide, and streptomycin, were also
administered for longer in patients with sputum SPCN
than in those without sputum SPCN, although themear (solid line) and positive sputum mycobacterial culture
g (>1+) at the start of treatment (A), and patients with and
but culture-negative.
Table 2 Multivariate logistic regression for sputum SPCN
in TB patients
Characteristics Multivariate
p value OR (95% C.I.)
Age, per 1 year increment 0.826
Gender, male vs. female 0.453
Cavitation on chest X ray 0.001 2.217 (1.359 - 3.615)
High initial acid fast stain grading* <0.001 3.407 (2.090 - 5.553)
Smoking 0.047 1.690 (1.006 - 2.841)
Alcohol consumption 0.541
Diabetes mellitus 0.319
WBC (per 1 cell/dLdecrement) 0.590
Hemoglobin, (per 1 g/dLdecrement) 0.577
* > 1+; SPCN, smear positive but culture negative; OR: Odds ration; C.I.:
Confidence interval; WBC: White blood count.
Figure 3 Percentages of sputum SPCN in patients according to acid f
cavities < 4 cm, and cavities > 4 cm) on chest-X ray films (B).
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niazid. A small proportion of patients received fluoroqui-
nolones because of adverse effects to first line medications;
there was no difference in use of fluoroquinolones be-
tween two groups. Interestingly, we found that patients
with sputum SPCN received treatment for longer after the
last positive culture than did those without sputum SPCN
(261 ± 72 vs. 220 ± 73, respectively; P < 0.001).
The percentage of patients with culture positivity was
similarly low between the two groups after treatment for
5 months (0.9%, 1/111 vs. 2.0%, 14/689; P = 0.707); how-
ever, even after treatment for 9 months the percentage
of patients with smear positivity remained higher in pa-
tients with sputum SPCN than in those without it (5.4%,
6/111 vs. 0.6%, 4/689, respectively; P = 0.001). Finally, al-
though the 111 patients with sputum SPCN received
treatment for longer and had slower smear conversion
than the 689 patients without sputum SPCN, there wereast staining grade (A) and severity of cavitation (no cavities,
Table 3 Treatment and outcome of patients with and
without sputum SPCN
SPCN (+) SPCN (−) P value
N = 111 N = 689
Treatment regimen
Isoniazide (days) 289 ± 90 234 ± 71 p < 0.001
Rifampicin (days) 284 ± 91 235 ± 69 p < 0.001
Ethambutol (days) 228 ± 105 191 ± 96 p = 0.001
Pyrazinamide (days) 137 ± 136 90 ± 74 p = 0.001
Streptomycin (days)
(total cases)
84 ± 76 (18) 43 ± 34 (39) p = 0.036
Levofloxacin (days)
(total cases)
132 ± 141 (11) 172 ± 196 (17) p = 0.559
Moxifloxacin (days)
(total cases)
215 ± 120 (6) 162 ± 146 (13) p = 0.456
Treatment days after
final positive culture
261 ± 72 220 ± 73 p < 0.001
DOT 92 (83) 475 (69) p = 0.001
Complete treatment 109 (98) 679 (99) p = 0.677
Sputum smear and culture status during treatment
After treatment for 2 months
Smear positive 84 (76) 32 (5) p < 0.001*
Culture positive 22 (20) 50 (7) p < 0.001*
After treatment for
5 months
Smear positive 26 (23) 9 (1) p < 0.001*
Culture positive 1 (1) 14 (2) p = 0.707*
After treatment for
9 months
Smear positive 6 (5) 4 (1) p = 0.001*
Culture positive 0 (0) 6 (1) p = 0.407*
Relapse within 3 years 3 (3) 7 (1) p = 0.150*
Data are presented as N (%) or mean ± standard deviation; SPCN, smear-positive
but culture-negative; DOT, directly observed therapy.
*Fisher’s exact test.
Table 4 Characteristics of the 10 relapse casesa
No Sputum SPCN Co-morbidity C
1 No Nil N
2 No Nil N
3 No Nil N
4 No Alcoholism Y
5 Yes DM N
6# No DM Y
7 No DM Y
8 Yes Alcoholism N
9 Yes DM/Alcoholism Y
10 No Nil Y
#MDR-TB while relapse; SPCN (smear positive but culture negative); DM, diabetes melli
Z, Pyrazinamide.
aPatients who died during the study were excluded.
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completed treatment rate (98% vs. 99%, respectively, P =
0.677) and relapse rate after follow-up for 3 years (3% vs.
1%, respectively, P = 0.150). The data regarding relapsed
cases are summarized in Table 4.
Taken together, our data show that sputum culture con-
version and relapse rates are not affected by the sputum
SPCN, possibly because patients with SPCN received
treatment for longer than those without sputum SPCN.
Discussion
This study aimed to investigate the risk factors and clinical
impact of the phenomenon of sputum SPCN. We found
that severe pulmonary TB, as evidenced both by cavitation
formation on CXR and high sputum AFS grading, and
smoking contributed to the occurrence of sputum SPCN
during treatment. Patients with sputum SPCN received
continuation phase treatment for longer than patients
without sputum SPCN; however, the relapse rate within
3 years after completion of treatment was similar between
the two groups.
Our data showed cavitation on CXR is an important
risk factor for sputum SPCN. Cavitation formation, a
well-known characteristic presentation of TB infection,
is believed to result from caseous granulomatous inflam-
mation. With advances in knowledge regarding TB im-
munity, granuloma formation has been subdivided into
highly-structured solid granulomas that contain Mtb and
caseous granulomas with less-organized structures and
liquefied centers, which lead to cavity formation [14,15].
Therefore, the strong correlation between cavitation and
the occurrence of SPCN mycobacteria indicates that
caseous granulomas, which contain numerous Mtb re-
leased from dead macrophages, may be the major source
of SPCN mycobacteria. We therefore surmised that spu-
tum SPCN may be a clinical indicator of host-pathogen
interactions in the lungs during TB infection.XR (cavity) DOT Treatment regimen
O Yes HER (194 d), Z (8 d)
O No HER (184 d), Z (63 d)
O Yes HER (182 d), Z (77 d)
es Yes HER (328 d), Z (17 d)
o Yes HER (252 d), Z (84 d)
es Yes HR (539 d), EZ (32 d)
es No HER (310d), Z (30 d)
o Yes HER (358 d), Z (12 d)
es Yes HER (343 d)
es Yes HR (231 d), E (21 d), Z (15 d)
tus; DOT, directly observed therapy; H, Isoniazide; E, Ethambutol; R, Rifampicin;
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be dead bacilli; however, accumulating evidence has
now shown that culturability does not equal viability.
Rather, SPCN bacilli can be viable but non-culturable
(VBNC) and culturability can be restored with add-
itional nutrient factors, including mycolic acid or pro-
teins called resuscitation-promoting factors [16,17].
Recently, Mukamolova et al. used culture medium with
and without resuscitation-promoting factors and dem-
onstrated not only the presence of VBNC Mtb but also
an increased proportion of VBNC Mtb during treat-
ment of pulmonary TB infection [18]. These findings
provide evidence of an adaptive phenotypic switch of
mycobacteria after exposure to anti-TB treatment; such
phenotype switches during treatment may lead to drug
resistance and relapse [19]. In this study, we found that
patients with sputum SPCN received treatment for lon-
ger after the final positive culture than patients without
sputum SPCN (261 ± 72 vs. 220 ± 73, respectively; P <
0.001) (Table 3), the duration of treatment having been
decided by the TB committees in each TB referral
center. When faced with sputum smear-positivity near
the end of the scheduled treatment course without
other evidence of treatment failure, members of these
committees tended to suggest continuation of treat-
ment and follow-up of culture results rather than im-
mediate modification of the drug regimen. The final
treatment outcome and relapse rate were similar be-
tween the two groups. Importantly, the three patients
who relapsed with sputum SPCN during initial treatment
did not develop any new drug resistance. Therefore, our
data provide evidence that continuation of treatment may
be an acceptable and practical strategy for treating patients
with sputum SPCN. However, more studies are needed to
establish the best treatment regimen for these patients.
The long turnaround time for culture results creates sev-
eral clinical dilemmas when treating patients with severe
TB and sputum SPCN. Persistence of positive AFS in spu-
tum often leads to prolonged isolation and suspicion of
treatment failure [7,8]. Our data show that sputum SPCN
mostly develops 157 ± 95 days after the start of treatment.
Specifically, at the end of the second month, 14.5% of all
patients (116/800) were smear-positive, but only 46.6%
(54/116) of these smear-positive patients were culture-
positive. Similarly, at the end of the fifth month, 4.4% of
all patients (35/800) were smear-positive, but only 28.6%
(10/35) of these smear-positive patients were culture-
positive. Our data are fully consistent with those of an-
other study conducted in Taiwan that reported 44.2% cul-
ture positivity (50/113) in 113 patients who were smear-
positive at the end of the second month [3]. The data at
the end of the fifth month are also consistent with those of
our previous study, which showed only 25.2% (28/113)
culture positivity in patients who were smear-positive atthe end of the fifth month [5]. This longitudinal study
showed that SPCN develops as early as 30 days after initi-
ating treatment and is rarely found after 240 days of treat-
ment (Figure 2). Therefore, AFS alone should not be used
as the sole means of assessing treatment response during
this period. Instead, as we showed in our previous study,
multi-dimensional assessment, including culture conver-
sion after initial phase treatment, CXR improvement,
directly observed short-course therapy (DOTS), and
AFS grading ≥3+ or not are crucial to thorough evalu-
ation of treatment responses in patients with severe
pulmonary TB [5].
Interestingly, we identified smoking as a minor risk factor
for sputum SPCN in this study. Smoking, including passive
smoking, has been found to be associated with active TB in
Taiwan and other countries; the suppressive effect of smok-
ing on airway defense has been assumed to be the causative
factor [20-22]. Moreover, smoking was recently found to
affect the rate of 2-month culture conversion during treat-
ment [23]. However, whether the immune-suppressive
effects of smoking also contribute to the development of
sputum SPCN in pulmonary TB patients remains to be
clarified.
Finally, SPCN is especially important in countries with
limited laboratory capacity. In Taiwan, the laboratory
capacity is adequate and all sputum samples are sent for
both smear and culture. However, in many countries
diagnosis of TB and assessment of treatment outcome
still relies on sputum smear only. In these countries, the
strong possibility of SPCN during anti-TB treatment in
patients with severe TB infection should be taken into
account when assessing treatment failure. As we showed
in our previous study, multi-dimensional assessment,
quality patient supervision, and chest radiography are
crucial for avoiding unnecessary modification of treat-
ment regimens [5].
This study has several noteworthy limitations. First,
the viability of organisms in SPCN sputum cannot be
ascertained under routine standard culture conditions
without adding additional resuscitation factors. Second,
the standard decontamination procedures in sputum
processing can decrease culturability. We believe the
differential error was not caused by such an inhibitory
effect on culturability in this study because all cases had
positive cultures for Mtb in sputum on enrollment and
the inhibitory effect on culturability was the same for all
sputum samples throughout the study period. Third, we
totally excluded patients with non-tuberculous mycobac-
teria (NTM) in this study, and only AFS-positive organ-
isms that grew no colonies on either liquid or solid
media were classified as SPCN. Therefore, we postulate
that we may have underestimated the true prevalence of
sputum SPCN Mtb in this study, rather than amplified
it, if there was any NTM contamination.
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This study provides clinical evidence of the previously
ignored sputum SPCN phenomenon in patients with
pulmonary TB receiving treatment. We have shown that
severe TB infection, as evidenced by cavitation on CXR
and high AFS grading in sputum, is the critical risk fac-
tor; smoking also contributes to the occurrence of spu-
tum SPCN. Prolonging continuation phase treatment
while awaiting results of culture of smear-positive sam-
ples appears to be a practical and safe strategy with an
acceptable relapse rate; however, the ideal regimen for
such patients has not yet been established.
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